Cerus Corporation's Participation in the AABB Annual Meeting
Today, Cerus Corporation (NASDAQ: CERS) shared exciting news about its involvement in an important upcoming event in the field of transfusion medicine. The 2024 Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting will gather experts and industry leaders in a great venue. This year, the meeting is set to take place in Houston and is expected to feature various groundbreaking discussions and research presentations.
Highlights of Presentations
During the AABB Annual Meeting, Cerus will showcase a range of presentations that cover a variety of topics vital to blood safety and biotherapies. The company is particularly eager to present their findings during oral presentations and poster sessions, highlighting significant advances in research and product development.
Oral Presentations
Cerus has scheduled several oral presentations that will shed light on cutting-edge research and the application of their innovative technologies. For instance, among the presentations is a discussion about the ReCePI Phase III Clinical Trial, focusing on pathogen-reduced red cells and the outcomes related to cardiac surgery. This particular study aims to address issues surrounding acute kidney injury and explores the effectiveness of a unique treatment approach.
Moreover, another presentation will delve into the use of Sankey Diagrams to evaluate laboratory efficiencies when comparing the INTERCEPT Fibrinogen Complex against traditional methods. This analysis underlines how these innovations can enhance operational protocols within healthcare settings.
Poster Presentations
In addition to oral presentations, Cerus will feature multiple poster sessions. These sessions will present comprehensive evaluations regarding various technologies that significantly improve blood safety. Topics will include:
- The effectiveness of pathogen reduction in platelet concentrates over time using advanced detection systems.
- The development of next-gen illuminators designed for the photochemical inactivation of pathogens in platelet concentrates.
- Studies analyzing waste reduction benefits and cost savings tied to the implementation of pathogen-reduced treatments.
Such presentations not only highlight Cerus's commitment to innovation but also the company’s ongoing efforts to improve patient outcomes through safer blood products.
Industry Workshop
A significant event during the Annual Meeting will be an industry workshop hosted by Cerus on October 21, 2024. This workshop is titled Pathogen Reduced Blood Components – Current Experiences and Future Developments with the INTERCEPT Blood System. It promises to be an engaging session where industry experts will share insights and discuss future directions in pathogen reduction technologies.
Visit Cerus at the AABB Annual Meeting
Cerus representatives will be available at their exhibition booth (#431) during the meeting. Attendees are encouraged to stop by to learn more about the company's pioneering work in blood safety technology and explore their product offerings.
About Cerus Corporation
Based in Concord, California, Cerus Corporation is dedicated to protecting the global blood supply. As a leading provider of pathogen reduction systems, Cerus is at the forefront of developing technologies that ensure safe blood transfusions. Their flagship product, the INTERCEPT Blood System, is currently in use worldwide, receiving both FDA approval and C.E. mark, showcasing its efficacy and reliability.
PARTICULARLY FOR CONSUMERS, the INTERCEPT Blood System delivers great advantage in treating conditions linked to fibrinogen deficiency, especially in acute care settings. Additionally, the red blood cell system is in advanced clinical development, signaling further innovation on the horizon for Cerus.
Frequently Asked Questions
What is the significance of the AABB Annual Meeting for Cerus Corporation?
The AABB Annual Meeting is crucial for Cerus as it provides a platform to showcase their research innovations and engage with industry leaders to strengthen their commitment to blood safety.
What presentations will Cerus be conducting at the AABB?
Cerus will deliver several oral presentations and poster presentations addressing various studies on pathogen reduction technology and its applications in transfusion medicine.
What can attendees expect at the Cerus workshop?
The workshop will cover current experiences and future developments regarding the INTERCEPT Blood System, featuring expert speakers discussing their insights in the field.
Where can I find more information about Cerus Corporation?
Further details about Cerus Corporation and their products are available on their official website, where individuals can explore their technological advances in blood safety.
How does Cerus contribute to blood safety?
Cerus develops technologies aimed at pathogen reduction in blood products, thereby ensuring safer transfusions and better patient outcomes during critical medical procedures.
